Global Vaccine Patent Landscape Report 2024

Patent Landscape Report Coverage

The Global Vaccine Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for vaccines include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation associated with vaccines. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within vaccine technologies.

Key Inclusions

Patent Valuation Analysis

An evaluation and competitive benchmarking of key members of unique patent families are covered in the analysis for vaccine technologies. The important parameters have been taken into consideration including IP document, year of application, number of citations, time to expiry, and jurisdiction associated with vaccines.

Analysis of Patent Applications

A comprehensive summary of several patent applications which were filed across different jurisdictions for vaccine and their relative value are covered. The analysis will cover the capital in terms of innovation and innovation type.

Analysis of Granted Patents

Detailed analysis of the granted patents across different jurisdictions for vaccine and their relative value in the IP are covered in the final report.

What is a Vaccine?

A vaccine is a biological preparation that works to alert the immune system to identify and eliminate specific pathogens, like bacteria or viruses. It usually contains inactivated or weakened versions of the pathogen or any of its constituents, which stimulates the immune system and confers immunity against infections in the future. Immunizations are essential for preventing illness and safeguarding the general public's health.

The components of vaccines include pneumococcal, influenza, DTP, HPV, MMR, and COVID-19. The pneumococcal vaccine guards against infections brought on by the Streptococcus pneumoniae bacteria, which can cause sepsis, meningitis, and pneumonia. It lessens the frequency and intensity of these infections, especially in susceptible groups like young children and the elderly.

Vaccine Industry Growth Drivers

Advancements in Vaccine Technology is Expected to Boost the Patent Industry Growth

Improvements in vaccine efficacy, safety, and production speed facilitate the development of more focused and effective vaccinations. These developments improve disease prevention and control by enabling quick reactions to newly emerging pathogens. For instance, the next-generation mRNA-based flu vaccine from Moderna targets multiple influenza strains more successfully by employing cutting-edge technology. This development demonstrates how improvements in vaccine technology lead to a wider and more effective defence against infections that are constantly evolving.

There is an increase in patent activity which focuses on enhancing the performance of vaccines. There were 6,458 patents granted in 2022 which increased to 6,526 patent grants by 2023. Patents covering these technologies are crucial for companies and thus impact the vaccine patent landscape.

Increasing Incidence of Infectious Diseases is Expected to Propel Vaccine Patent Industry

The increased incidence of infectious diseases is driving the demand for vaccines as a critical tool for prevention and control. This growing need prompts ongoing vaccine development and distribution to manage and mitigate the impact of widespread infections.

Vaccine Patent Segmentation

Vaccine Patent Segmentation Analysis

The breakup based on Indication includes pneumococcal, influenza, DTP, HPV, MMR, and COVID-19. The seasonal flu, which is brought on by influenza viruses and can cause serious respiratory illnesses, is prevented by the influenza vaccine. It lowers the risk of hospitalizations and complications from the flu and is updated yearly to match circulating strains.

Vaccine Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for vaccine patents, having around 217,000+ patents. The presence of big companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the regional patent landscape significantly.

Patent Profile of Key Companies

Among the players with vaccine patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the vaccine field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Novartis AG

This company is based in Basel, Switzerland, and was established in 1996. Leading the way in global healthcare, the company offers a wide range of products, including vaccines made by its subsidiary Novartis Vaccines. Novartis is committed to improving public health globally by using cutting-edge approaches to the prevention and treatment of infectious diseases.

Immatics Biotechnologies Gmbh

This company is based in Tübingen, Germany, and was established in 2000. The company leverages its experience...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include Glaxosmithkline Biolog SA, Merck & Co Inc., Sanofi, Massachusetts Inst Technology, Inst Nat Sante Rech Med, Dana Farber Cancer Inst Inc, Regeneron Pharma, Human Genome Sciences Inc., Imperial College Innovations Ltd, among others.

Reasons to Purchase this Report

The vaccine patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and makes it understandable which companies have important patents in this field of vaccines.
• Innovation Insights: The patent analysis reveals new innovations and technologies in vaccines.
• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry within the vaccine patent landscape.
• Risk Assessment: In technology-intensive fields such as vaccines, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Vaccine Patent Landscape Report

• Who are the key players in the vaccine patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in vaccine patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the vaccine industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in vaccines?
• What are the challenges and opportunities in the vaccine patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in vaccines?

Related Reports

Global Travel Vaccines Market

Global Autogenous Vaccines Market

Global Meningococcal Vaccines Market